What happened
ByteDance created Anew Labs, a new biotech company focused on AI‑enabled drug discovery, securing $290 million in funding at a $1.5 billion valuation.
ByteDance announced the spin‑out of its internal AI‑for‑science team into a standalone biotech startup called Anew Labs. The company raised $290 million in a financing round led by HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment, valuing the firm at $1.5 billion.
Anew Labs employs 36 staff across offices in Shanghai, Singapore, and San Jose, and is led by Kai Liu, the former head of ByteDance’s AI‑for‑science division. The startup builds on ByteDance’s open‑source life‑science AI tools, including the protein‑structure predictor Protenix and the protein‑binder generator PXDesign. In its debut, Anew Labs released preprint research describing a thermodynamic model for protein‑drug binding and a that can generate small molecules, peptides, and antibodies. Its first drug candidate is a small‑molecule inhibitor of IL‑17, currently in the lead‑optimization phase of preclinical development, and is positioned to compete with existing IL‑17 antibody therapies from companies such as Novartis, Eli Lilly, and UCB. The company declined media interviews pending ByteDance’s approval.
Why it matters
The launch signals China’s entry into the high‑stakes AI‑driven pharmaceutical arena, challenging the dominance of Western players and testing whether AI can accelerate the notoriously slow drug‑development .
Anew Labs’ emergence illustrates a shift in the global AI‑drug‑discovery landscape, where Chinese tech firms are now directly entering biotech. The $290 million infusion provides substantial resources to develop AI pipelines that could shorten hit‑finding cycles, a step that has historically been a bottleneck in early‑stage drug research. If the startup’s AI models prove effective, they could set new benchmarks for speed and cost‑efficiency, pressuring Western rivals to open their own research or form new partnerships. However, a 2026 Nature review cited in the article notes that most AI‑driven projects remain in preclinical stages, with few reaching Phase I or beyond, underscoring the risk that Anew Labs may face similar translational hurdles. The startup’s transparent research approach, contrasting with the more closed DeepMind‑Isomorphic Labs model, may also influence industry standards for data sharing and reproducibility.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
In AI, what are a model's "parameters"?
What to watch next
Observers will monitor Anew Labs’ progress on its IL‑17 candidate, any clinical‑stage milestones, and whether the startup can translate its AI models into approved medicines.
The timeline for Anew Labs’ IL‑17 candidate to enter animal studies and, eventually, human Phase I trials.
Any peer‑reviewed validation of the company’s thermodynamic binding model and diffusion‑based molecule generator.
Regulatory filings or partnerships with contract research organizations that could accelerate clinical development.
Potential follow‑on funding rounds or strategic alliances with larger pharmaceutical firms seeking AI‑generated assets.